Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antihypertensive Drug Effects on Long-Term Blood Pressure: An Individual-Level Data Meta-Analysis of Randomised Clinical Trials Publisher Pubmed



Canoy D1, 2 ; Copland E1 ; Nazarzadeh M1 ; Ramakrishnan R3 ; Pinhogomes AC4, 5 ; Salam A6, 7 ; Dwyer JP8 ; Farzadfar F9 ; Sundstrom J10 ; Woodward M6, 11 ; Davis BR12 ; Rahimi K1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Deep Medicine, Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, United Kingdom
  2. 2. NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  3. 3. National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  4. 4. School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom
  5. 5. Department of Community Medicine, Centre for Health Technology and Services Research, University of Porto, Porto, Portugal
  6. 6. The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
  7. 7. The George Institute for Global Health India, Hyderabad, India
  8. 8. Vanderbilt University Medical Center, Nashville, TN, United States
  9. 9. Endocrinology and Metabolism Institute, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Department of Medical Sciences, Uppsala Universitet, Uppsala, Sweden
  11. 11. The George Institute for Global Health UK, Imperial College London, London, United Kingdom
  12. 12. Department of Biostatistics, University of Texas School of Public Health, Houston, TX, United States

Source: Heart Published:2022


Abstract

Objective Evidence from randomised trials of pharmacological treatments on long-term blood pressure (BP) reduction is limited. We investigated the antihypertensive drug effects on BP over time and across different participant characteristics. Methods We conducted an individual patient-level data meta-analysis of 52 large-scale randomised clinical trials in the Blood Pressure Lowering Treatment Trialists’ Collaboration using mixed models to examine treatment effects on BP over 4 years of mean follow-up. Results There were 363 684 participants (42% women), with baseline mean age=65 years and mean systolic/ diastolic BP=152/87 mm Hg, and among whom 19% were current smokers, 49% had cardiovascular disease, 28% had diabetes and 69% were taking antihypertensive treatment at baseline. Drugs were effective in lowering BP showing maximal effect after 12 months and gradually attenuating towards later years. Based on measures taken ≥12 months postrandomisation, mean systolic/diastolic BP difference (95% CI) between more and less intense BP-lowering treatment was −11.1 (−11.3 to −10.8)/−5.6 (−5.7 to −5.4) mm Hg; between active treatment and placebo was −5.1 (−5.3 to −5.0)/−2.3 (−2.4 to −2.2) mm Hg; and between active and control arms for drug comparison trials was −1.4 (−1.5 to −1.3)/−0.6 (−0.7 to −0.6) mm Hg. BP reductions were observed across different baseline BP values and ages, and by sex, history of cardiovascular disease and diabetes and prior antihypertensive treatment use. Conclusion These findings suggest that BP-lowering pharmacotherapy is effective in lowering BP, up to 4 years on average, in people with different characteristics. Appropriate treatment strategies are needed to sustain substantive long-term BP reductions. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Related Docs
Experts (# of related papers)